


“One Pill Fits For All” Approach Has to Stop!



Practical Recommendations

- Labellings should include research-proven dosage recommendations and ADR for different genders
- Role of Inclusive Trial Design & Regulatory Guidance
- Advocate more **women's representation** in clinical, disease research trials

Conclusion Statement

As clinicians, providing treatment is essential for our patients, but we must always take into consideration of gender differences and ensure we tailor **personalised treatment ALWAYS!**

References & Declaration



Chong Zhan Xuan (ME224)

